Genentech, a member of the Roche group (PINK:RHHBY), said today that it won FDA clearance for its Lucentis (ranibizumab injection) pre-filled syringes. The anti-VEGF medicine is FDA-approved to treat wet age-related macular degeneration and macular edema after retinal vein occlusion.
The pre-filled syringe enables physicians to eliminate steps in preparation and administration process, the company reported, such as disinfecting the vial, attaching a filter needle,and drawing the medicine from the vial using the needle.
Physicians have to attach the injection needle to the syringe and adjust to the proper dose, the San Francisco, Calif.-based company said.
Get the full story on our sister site, Drug Delivery Business News.
The post FDA approves Genentech’s Lucentis pre-filled ranibizumab syringe appeared first on MassDevice.
from MassDevice http://ift.tt/2eBrWtE
Cap comentari:
Publica un comentari a l'entrada